1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > BUSINESS
BUSINESS
- Leqembi’s April-June Sales Up 2.2-Fold from Prior Quarter: Eisai
August 2, 2024
- Maruho, Meiji to End Co-Promotion of Amenalief in Japan
August 2, 2024
- Toa Eiyo to Downsize Workforce by 100 through Voluntary Buyout
August 1, 2024
- Sumitomo Announces Its Largest-Yet Job Cut of 700 Employees in Japan
August 1, 2024
- SanBio’s Cell Therapy Akuugo Scores Conditional Approval
August 1, 2024
- Daiichi Sankyo’s Q1 Sales Grow 24% as Mainstays Fare Well
August 1, 2024
- Chugai to Develop Roche’s PI3K Inhibitor Inavolisib in Japan
August 1, 2024
- AstraZeneca Files Tagrisso, Imfinzi for Post-Chemoradiation Setting
August 1, 2024
- Twymeeg Champion Trophy Winner in June GP Rep Promotion Rankings: Intage
August 1, 2024
- Local Anesthetic Runs Short in Japan Due to Curbed Supply of Sandoz’ Anapeine
July 31, 2024
- Novo’s Cell Therapy Partner Heartseed Goes Public on TSE
July 31, 2024
- Foreign Pharma Sales in Japan Likely to Fall for 2nd Straight Year in 2024: Fuji Keizai
July 31, 2024
- JCR Ditches Temcell Program for nHIE Indication
July 31, 2024
- Chugai to Practically Scrap Mandatory Retirement Age in 2026
July 30, 2024
- Recordati Japan on Hunt for Rare Disease Assets at Risk of Drug Loss
July 30, 2024
- Astellas Gets EMA Blessing for Gastric Cancer Drug Zolbetuximab
July 30, 2024
- Padcev-Keytruda Nears EU Nod for 1st Line Bladder Cancer
July 30, 2024
- Xocova Grabs Near-70% Share among Oral COVID Meds in Japan: Shionogi
July 30, 2024
- Mitsubishi Tanabe to Launch Voluntary Buyout Program
July 30, 2024
- AZ, United Immunity to Tie Up on Drug Delivery Tech Research
July 29, 2024
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…